C4 Therapeutics (CCCC) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

C4 Therapeutics

NasdaqGS•Healthcare•Biotechnology

$3.47+0.06(0.02%)Market open

Market Cap

$450.90M

P/S

12.9x

P/B

1.8x

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1. The company is also developing oncology product candidate, CFT8919, an orally bioavailable, allosteric, mutant-selective bidac degrader of epidermal growth factor receptor, with an L858R mutation in non-small cell lung cancer; and new degraders focused on inflammation, neuroinflammation, and neurodegeneration. It has strategic collaborations F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Betta Pharmaceuticals Co. Ltd., and Merck KGAA. Additionally, it has a collaboration agreement with Roche Holding AG for the development of Degrader-Antibody Conjugates for cancer treatment. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

How this company scores

AverageMetricSide Score: 48/100

Strongest: Balance Sheet & Red Flags (15/25); weakest: Cash & Earnings Quality (8/25).

Profitability13/25

Growth12/25

Balance Sheet & Red Flags15/25

Cash & Earnings Quality8/25

Strengths

Interest easily coveredProfit converts from growthNet cash positionImproving margins

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/S · 12.9x5y range 2.8x – 46.1x

Currently above its 20-quarter median.

P/B · 1.8x5y range 0.4x – 5.8x

Currently above its 20-quarter median.

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 8 of the last 8 quarters — earnings are not translating to cash.

Price & Volume

Market Cap $450.90M

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $35.04M
Q. Revenue: $6.64M
TTM EBITDA: $-109.94M
TTM Op. Income: $-111.77M
Q. Op. Income: $-26.42M
TTM Net Income: $-101.42M
Q. Net Income: $-23.64M
EPS: $-0.18
Shares Out.: $130.70M

$35.04M in TTM revenue grew 2.3% YoY, reaching $6.64M last quarter. TTM EBITDA of $-109.94M and TTM operating income of $-111.77M show growth is flowing through to the bottom line. However, net income is negative at $101.42M — growth is not yet reaching the bottom line. Over the past year, TTM revenue is up 2% — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

EBITDA Margin: -392.8%
Op. Margin: -397.9%
Net Margin: -355.9%

Op. margin of -397.9% is up 43.1% YoY — cost efficiency is improving. Net margin at -355.9% Over the past year, operating margin is up 10% — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: 12.9x
P/B Ratio: 1.8x

P/S of 12.9x and P/B of 1.8x. P/S is high, meaning growth expectations are priced in.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $359.40M
Cash: $78.61M
Long-Term Debt: N/A
Book Value: $247.26M
D/E Ratio: N/A
Debt/EBITDA: N/A

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $-1.57M
TTM Free Cash Flow: $-85.39M
FCF Margin: -243.7%
FCF / Net Income: 0.8

TTM FCF of $-85.39M on $-1.57M in operating cash flow. The FCF / Net Income ratio of 0.8x means free cash flow covers net income — earnings are backed by cash. Across the last 8 quarters, free cash flow has risen for 2 consecutive quarters — an improving trend.